Accuray Incorporated (LON:0H8I)
1.230
-0.021 (-1.67%)
At close: Jun 13, 2025
Accuray Revenue
Accuray had revenue of $113.24M USD in the quarter ending March 31, 2025, with 11.98% growth. This brings the company's revenue in the last twelve months to $465.25M, up 8.06% year-over-year. In the fiscal year ending June 30, 2024, Accuray had annual revenue of $446.55M, down -0.24%.
Revenue (ttm)
$465.25M
Revenue Growth
+8.06%
P/S Ratio
0.26
Revenue / Employee
$471.38K
Employees
987
Market Cap
93.19M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 446.55M | -1.05M | -0.24% |
Jun 30, 2023 | 447.61M | 17.70M | 4.12% |
Jun 30, 2022 | 429.91M | 33.62M | 8.48% |
Jun 30, 2021 | 396.29M | 13.36M | 3.49% |
Jun 30, 2020 | 382.93M | -35.86M | -8.56% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Accuray News
- 10 days ago - Accuray restructures debt, secures new $190M financing; shares down - Seeking Alpha
- 10 days ago - Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities - PRNewsWire
- 18 days ago - Accuray to Participate in the Jefferies Global Healthcare Conference 2025 - PRNewsWire
- 5 weeks ago - Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 - PRNewsWire
- 6 weeks ago - Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System - PRNewsWire
- 6 weeks ago - Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade) - Seeking Alpha
- 6 weeks ago - Accuray outlines Q4 revenue guidance with $10M-$15M impact from China tariffs - Seeking Alpha
- 6 weeks ago - Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript - Seeking Alpha